Presentation is loading. Please wait.

Presentation is loading. Please wait.

Concentrations of abemaciclib in plasma and cerebrospinal fluid (CSF).

Published byΦιλόθεος Κωνσταντόπουλος Modified over 5 years ago

Similar presentations

Presentation on theme: "Concentrations of abemaciclib in plasma and cerebrospinal fluid (CSF)."— Presentation transcript:

1 Concentrations of abemaciclib in plasma and cerebrospinal fluid (CSF).
Concentrations of abemaciclib in plasma and cerebrospinal fluid (CSF). Geometric mean time course of abemaciclib plasma concentration (A) after single oral dose of abemaciclib ranging from 50 to 275 mg and (B) at steady state on once-daily (Q24H) and twice-daily (Q12H) schedules. Observations below the limit of quantitation of the assay were excluded from the analysis. C, paired plasma and cerebrospinal fluid concentrations of abemaciclib at steady state. Amita Patnaik et al. Cancer Discov 2016;6: ©2016 by American Association for Cancer Research

Download ppt "Concentrations of abemaciclib in plasma and cerebrospinal fluid (CSF)."

Similar presentations

Dose and range (mg/kg body weight)

Dose and range (mg/kg body weight)
Fadiea Al-Aieshy   PhD-student, MSc Pharm

Fadiea Al-Aieshy   PhD-student, MSc Pharm
Volume 1, Issue 3, Pages (November 2015)

Volume 1, Issue 3, Pages (November 2015)
A, Pyrimethamine serum levels (4 and 24 hours after a dose) of children given 1 mg pyrimethamine per kilogram daily. B, Pyrimethamine serum levels (4 and.

A, Pyrimethamine serum levels (4 and 24 hours after a dose) of children given 1 mg pyrimethamine per kilogram daily. B, Pyrimethamine serum levels (4 and.
Enhanced DNA damage in IDH1 mutant glioma cells.

Enhanced DNA damage in IDH1 mutant glioma cells.
Dose-escalation patient response.

Dose-escalation patient response.
IL-1β stimulates CXCL5 and CXCL8 gene expression and protein secretion in A549 cells in a time- and dose-dependent manner. IL-1β stimulates CXCL5 and CXCL8.

IL-1β stimulates CXCL5 and CXCL8 gene expression and protein secretion in A549 cells in a time- and dose-dependent manner. IL-1β stimulates CXCL5 and CXCL8.
Proof-of-concept clinical studies validating AZD9291 as a mutant-selective EGFR kinase T790M inhibitor. Proof-of-concept clinical studies validating AZD9291.

Proof-of-concept clinical studies validating AZD9291 as a mutant-selective EGFR kinase T790M inhibitor. Proof-of-concept clinical studies validating AZD9291.
Breast cancer. Breast cancer. A, antitumor activity of abemaciclib in a human xenograft model (T47D) of ER-positive, HER2-negative breast cancer. Athymic.

Breast cancer. Breast cancer. A, antitumor activity of abemaciclib in a human xenograft model (T47D) of ER-positive, HER2-negative breast cancer. Athymic.
Treatment with BLU9931 leads to tumor regression in the FGF19-overexpressing PDX-derived xenograft LIXC012. Treatment with BLU9931 leads to tumor regression.

Treatment with BLU9931 leads to tumor regression in the FGF19-overexpressing PDX-derived xenograft LIXC012. Treatment with BLU9931 leads to tumor regression.
NSCLC. NSCLC. A, antitumor activity of abemaciclib in 4 KRAS-mutant (NCI-H358, NCI-H2122, NCI-H441, NCI-H460) and 2 KRAS wild-type (WT; NCI-H1650, NCI-H1975)

NSCLC. NSCLC. A, antitumor activity of abemaciclib in 4 KRAS-mutant (NCI-H358, NCI-H2122, NCI-H441, NCI-H460) and 2 KRAS wild-type (WT; NCI-H1650, NCI-H1975)
Nat. Rev. Cardiol. doi: /nrcardio

Nat. Rev. Cardiol. doi: /nrcardio
Penetration of fusidic acid and rifampicin into cerebrospinal fluid in low-grade inflammatory meningitis caused by Staphylococcus epidermidis  A. Hedberg,

Penetration of fusidic acid and rifampicin into cerebrospinal fluid in low-grade inflammatory meningitis caused by Staphylococcus epidermidis  A. Hedberg,
Diagnosis, risk classification, and recommended management of a BRUE

Diagnosis, risk classification, and recommended management of a BRUE
Tumor development of poorly immunogenic LLC and B16F10 cells modified to produce GM-CSF was markedly inhibited. Tumor development of poorly immunogenic.

Tumor development of poorly immunogenic LLC and B16F10 cells modified to produce GM-CSF was markedly inhibited. Tumor development of poorly immunogenic.
Inhibition of FGFR signaling and tumor growth in SNU-16 xenograft model by administration of E7090. Inhibition of FGFR signaling and tumor growth in SNU-16.

Inhibition of FGFR signaling and tumor growth in SNU-16 xenograft model by administration of E7090. Inhibition of FGFR signaling and tumor growth in SNU-16.
by Hideki Yoshioka, Hiromi Sato, Hiroto Hatakeyama, and Akihiro Hisaka

by Hideki Yoshioka, Hiromi Sato, Hiroto Hatakeyama, and Akihiro Hisaka
Treatment with BLU9931 leads to tumor regression in the FGF19-amplified Hep 3B liver cancer model. Treatment with BLU9931 leads to tumor regression in.

Treatment with BLU9931 leads to tumor regression in the FGF19-amplified Hep 3B liver cancer model. Treatment with BLU9931 leads to tumor regression in.
Geometric mean concentration-time profiles of (A) racemic BUP, R-BUP, and S-BUP; (B) racemic OHBUP, RR-OHBUP, and SS-OHBUP; (C) racemic ERY, SR-ERYHBUP,

Geometric mean concentration-time profiles of (A) racemic BUP, R-BUP, and S-BUP; (B) racemic OHBUP, RR-OHBUP, and SS-OHBUP; (C) racemic ERY, SR-ERYHBUP,
Plasma concentration–time profile, relative bioavailability and pharmacokinetic (PK) parameters of 4 mg TAK-228 in the single-agent QD PK run-in period,

Plasma concentration–time profile, relative bioavailability and pharmacokinetic (PK) parameters of 4 mg TAK-228 in the single-agent QD PK run-in period,

Similar presentations

Ads by Google